Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Kala Pharmaceuticals	Homology Medicines	VistaGen Therapeutics	Mawson Infrastructure Group	KemPharm
Symbol	NASDAQ:KALA	NASDAQ:FIXX	NASDAQ:VTGN	OTCMKTS:WIZP	NASDAQ:KMPH
Price Information
Current Price	$3.61	$6.48	$2.90	$0.81	$10.81
50-Day Moving Average	$5.28	$6.78	$2.79	$0.78	$12.08
52-Week Low	$3.55	$5.94	$0.56	$0.07	$4.54
52-Week High	$10.99	$16.38	$3.55	$1.45	$22.08
MarketRank™
Overall Score	1.5	1.3	1.6	0.6	1.4
Analysis Score	3.4	3.4	3.5	0.0	2.3
Community Score	2.6	2.5	2.9	3.0	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	1.7	0.0	1.7
Earnings & Valuation Score	0.6	0.0	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	N/A	Buy
Consensus Price Target	$22.00	$24.20	$6.50	N/A	$12.00
% Upside from Price Target	509.42% upside	273.46% upside	124.14% upside	N/A	11.01% upside
Trade Information
Market Cap	$233.35 million	$369.88 million	$555.00 million	$393.92 million	$366.35 million
Beta	0.44	-0.4	0.88	1.58	3.34
Average Volume	2,119,133	582,324	3,470,238	141,517	860,690
Sales & Book Value
Annual Revenue	$6.36 million	$2.70 million	$1.09 million	N/A	$13.29 million
Price / Sales	36.69	136.99	509.18	N/A	27.57
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.78 per share	$4.33 per share	$0.51 per share	$0.03 per share	($14.64) per share
Price / Book	2.03	1.50	5.69	N/A	-0.74
Profitability
Net Income	$-104,330,000.00	$-128,690,000.00	$-17,930,000.00	$-3,450,000.00	$-12,760,000.00
EPS	($1.99)	($2.80)	($0.49)	($0.37)	($3.00)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	72.07
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-1,318.03%	-300.57%	N/A	N/A	-74.21%
Return on Equity (ROE)	-101.43%	-49.59%	-38.91%	N/A	N/A
Return on Assets (ROA)	-48.93%	-38.35%	-29.40%	-85.32%	-1.33%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.66%	N/A	N/A	N/A	N/A
Current Ratio	8.96%	10.76%	24.85%	1.13%	20.70%
Quick Ratio	8.55%	10.76%	24.86%	1.13%	20.70%
Ownership Information
Institutional Ownership Percentage	56.89%	50.32%	73.89%	N/A	8.23%
Insider Ownership Percentage	34.15%	21.70%	0.23%	N/A	1.30%
Miscellaneous
Employees	188	205	11	2	22
Shares Outstanding	64.64 million	57.08 million	191.38 million	486.32 million	33.89 million
Next Earnings Date	8/5/2021 (Estimated)	8/9/2021 (Estimated)	8/12/2021 (Estimated)	N/A	8/11/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium cmlviz.com - July 23 at 1:15 PM
	KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. wallstreet-online.de - July 23 at 1:15 PM
	KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. marketwatch.com - July 23 at 1:15 PM
	KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. - Yahoo Finance finance.yahoo.com - July 21 at 11:23 PM
	Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - KPVI News 6 kpvi.com - July 21 at 6:22 PM
	Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies? - Salamanca Press salamancapress.com - July 21 at 1:22 PM
	Should You Sell KemPharm Inc (KMPH) in Biotechnology Industry? - InvestorsObserver investorsobserver.com - July 21 at 1:22 PM
	KemPharm launches ADHD treatment AZSTARYS in U.S. - Seeking Alpha seekingalpha.com - July 21 at 1:22 PM
	KemPharm Announces U.S. Launch of ADHD Treatment AZSTARYS By Corium - Benzinga benzinga.com - July 21 at 8:46 AM
	KemPharm Announces US Launch of Innovative ADHD Treatment - GlobeNewswire globenewswire.com - July 21 at 8:46 AM
	KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. finance.yahoo.com - July 21 at 8:46 AM
	Zacks: Brokerages Expect KemPharm, Inc. (NASDAQ:KMPH) Will Post Quarterly Sales of $12.10 Million americanbankingnews.com - July 19 at 5:02 AM
	Boom Or Bust: What Are KemPharm Inc.'s (NASDAQ:KMPH) Future Prospects? - Marketing Sentinel marketingsentinel.com - July 17 at 8:16 AM
	KemPharm, Inc. (NASDAQ:KMPH) Expected to Post Earnings of $0.23 Per Share americanbankingnews.com - July 17 at 7:16 AM
	InvestorNewsBreaks – KemPharm Inc. (NASDAQ: KMPH) Announces $39M Warrant Exchange Offering - StreetInsider.com streetinsider.com - July 15 at 6:09 PM
	KemPharm, Inc. (NASDAQ:KMPH) CEO Buys $21,645.00 in Stock americanbankingnews.com - July 15 at 9:08 AM
	Comparing KemPharm (NASDAQ:KMPH) & Catalyst Biosciences (NASDAQ:CBIO) americanbankingnews.com - July 11 at 7:22 AM
	KemPharm, Inc. (NASDAQ:KMPH) is a hot stock at the moment stocksregister.com - July 10 at 3:10 PM
	Is KemPharm Inc (KMPH) Stock at the Top of the Biotechnology Industry? - InvestorsObserver investorsobserver.com - July 6 at 2:48 PM
	Comparing Theratechnologies (NASDAQ:THTX) and KemPharm (NASDAQ:KMPH) americanbankingnews.com - July 5 at 1:06 PM
	KEMPHARM, INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.com marketscreener.com - July 2 at 6:05 PM
	As The Stock Rises By 14.46% Year-To-Date, KemPharm Inc. (NASDAQ: KMPH)'S Stock Continues To Progress In 2021 - Marketing Sentinel marketingsentinel.com - July 1 at 1:23 PM
	Costochondritis Treatment Market May See Big Move 2026: KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc. – The Manomet Current - The Manomet Current manometcurrent.com - June 30 at 12:04 PM
	Is KemPharm Inc (KMPH) A Good Stock To Buy? - Yahoo Finance finance.yahoo.com - June 29 at 10:54 AM
	Is KemPharm Inc (KMPH) A Good Stock To Buy? finance.yahoo.com - June 29 at 10:54 AM

Date	Company	Brokerage	Action
7/7/2021	Homology Medicines	Chardan Capital	Reiterated Rating
6/4/2021	Kala Pharmaceuticals	HC Wainwright	Reiterated Rating
5/19/2021	VistaGen Therapeutics	Robert W. Baird	Initiated Coverage
5/18/2021	Homology Medicines	Canaccord Genuity	Lower Price Target
5/12/2021	Kala Pharmaceuticals	HC Wainwright	Lower Price Target
5/7/2021	Homology Medicines	Oppenheimer	Lower Price Target
5/6/2021	Kala Pharmaceuticals	HC Wainwright	Reiterated Rating
3/10/2021	KemPharm	HC Wainwright	Reiterated Rating
3/4/2021	KemPharm	HC Wainwright	Downgrade
3/1/2021	Homology Medicines	Stifel Nicolaus	Initiated Coverage
2/18/2021	VistaGen Therapeutics	Jefferies Financial Group	Initiated Coverage
2/17/2021	Kala Pharmaceuticals	HC Wainwright	Reiterated Rating
1/25/2021	KemPharm	Roth Capital	Initiated Coverage
1/4/2021	VistaGen Therapeutics	William Blair	Upgrade
12/22/2020	VistaGen Therapeutics	Maxim Group	Boost Price Target
12/14/2020	Homology Medicines	HC Wainwright	Reiterated Rating
11/30/2020	Kala Pharmaceuticals	Northland Securities	Reiterated Rating
10/28/2020	Kala Pharmaceuticals	Wedbush	Boost Price Target
10/8/2020	VistaGen Therapeutics	Aegis	Initiated Coverage
10/5/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
9/14/2020	Kala Pharmaceuticals	Jefferies Financial Group	Downgrade
8/18/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
8/18/2020	KemPharm	HC Wainwright	Reiterated Rating
8/11/2020	Homology Medicines	Oppenheimer	Lower Price Target
8/11/2020	Homology Medicines	HC Wainwright	Lower Price Target
8/11/2020	VistaGen Therapeutics	Maxim Group	Reiterated Rating
8/10/2020	Homology Medicines	Chardan Capital	Reiterated Rating
8/7/2020	Kala Pharmaceuticals	Northland Securities	Reiterated Rating
8/4/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
7/23/2020	Kala Pharmaceuticals	Northland Securities	Initiated Coverage
6/26/2020	VistaGen Therapeutics	Maxim Group	Reiterated Rating
6/25/2020	Homology Medicines	Bank of America	Initiated Coverage
6/25/2020	Homology Medicines	FIX	Initiated Coverage
6/14/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
6/2/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
5/31/2020	Homology Medicines	Chardan Capital	Reiterated Rating
5/29/2020	Kala Pharmaceuticals	Oppenheimer	Initiated Coverage
5/29/2020	VistaGen Therapeutics	Maxim Group	Initiated Coverage
5/27/2020	Kala Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
5/27/2020	Kala Pharmaceuticals	HC Wainwright	Reiterated Rating
5/20/2020	KemPharm	HC Wainwright	Lower Price Target
5/13/2020	Homology Medicines	Royal Bank of Canada	Initiated Coverage
5/11/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
5/8/2020	Kala Pharmaceuticals	HC Wainwright	Boost Price Target
5/4/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
4/29/2020	VistaGen Therapeutics	Maxim Group	Initiated Coverage
4/22/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
4/13/2020	Kala Pharmaceuticals	HC Wainwright	Reiterated Rating
3/29/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
3/18/2020	Kala Pharmaceuticals	HC Wainwright	Boost Price Target
3/17/2020	Kala Pharmaceuticals	Wedbush	Reiterated Rating
3/16/2020	Homology Medicines	FIX	Upgrade
3/15/2020	Homology Medicines	Oppenheimer	Upgrade
3/13/2020	Homology Medicines	Chardan Capital	Reiterated Rating
3/13/2020	Homology Medicines	HC Wainwright	Reiterated Rating
3/13/2020	Homology Medicines	Robert W. Baird	Boost Price Target
2/24/2020	Homology Medicines	Chardan Capital	Initiated Coverage
2/6/2020	Homology Medicines	HC Wainwright	Reiterated Rating
12/19/2019	KemPharm	HC Wainwright	Reiterated Rating
12/2/2019	VistaGen Therapeutics	Chardan Capital	Reiterated Rating
11/20/2019	KemPharm	HC Wainwright	Reiterated Rating
11/14/2019	VistaGen Therapeutics	William Blair	Downgrade
11/3/2019	VistaGen Therapeutics	Chardan Capital	Reiterated Rating
11/1/2019	Homology Medicines	Oppenheimer	Initiated Coverage
10/31/2019	Homology Medicines	FIX	Initiated Coverage
10/15/2019	VistaGen Therapeutics	Maxim Group	Set Price Target
10/9/2019	VistaGen Therapeutics	William Blair	Reiterated Rating
10/8/2019	VistaGen Therapeutics	Maxim Group	Set Price Target
9/24/2019	Homology Medicines	HC Wainwright	Set Price Target
9/9/2019	Homology Medicines	Robert W. Baird	Initiated Coverage
9/5/2019	KemPharm	HC Wainwright	Reiterated Rating
9/5/2019	KemPharm	Roth Capital	Downgrade
8/28/2019	VistaGen Therapeutics	William Blair	Initiated Coverage
7/29/2019	VistaGen Therapeutics	Chardan Capital	Reiterated Rating
7/26/2019	Homology Medicines	Canaccord Genuity	Set Price Target
7/22/2019	VistaGen Therapeutics	Chardan Capital	Downgrade
6/19/2019	KemPharm	HC Wainwright	Initiated Coverage
6/11/2019	Homology Medicines	HC Wainwright	Set Price Target
5/23/2019	KemPharm	Oppenheimer	Lower Price Target
5/2/2019	VistaGen Therapeutics	Maxim Group	Set Price Target
3/6/2019	VistaGen Therapeutics	Maxim Group	Reiterated Rating
11/15/2018	KemPharm	Oppenheimer	Set Price Target
11/4/2018	VistaGen Therapeutics	Oppenheimer	Set Price Target
10/31/2018	KemPharm	Oppenheimer	Set Price Target
10/25/2018	VistaGen Therapeutics	Maxim Group	Set Price Target
10/25/2018	KemPharm	Oppenheimer	Set Price Target
10/11/2018	KemPharm	Oppenheimer	Set Price Target
10/3/2018	VistaGen Therapeutics	Maxim Group	Set Price Target
9/21/2018	KemPharm	Oppenheimer	Initiated Coverage
9/21/2018	KemPharm	CIBC	Reiterated Rating
9/20/2018	KemPharm	Oppenheimer	Set Price Target
9/13/2018	VistaGen Therapeutics	Maxim Group	Set Price Target
9/5/2018	VistaGen Therapeutics	Maxim Group	Set Price Target
8/14/2018	KemPharm	Canaccord Genuity	Reiterated Rating
8/9/2018	KemPharm	Oppenheimer	Set Price Target

(Data available from 7/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources